Jasper Therapeutics FY2022 net loss $37.7M; expands briquilimab to chronic urticaria, raises $101.4M

Jasper Therapeutics, Inc.

FY2022 net loss $37.7M vs $30.6M in 2021; R&D $34.6M, G&A $16.6M.
Cash $38.3M at Dec 31; raised $101.4M net in Jan 2023; expects funding through 2024.
Expanding briquilimab to chronic spontaneous urticaria; 12/12 AML engraftment, 8/12 relapse-free at 1yr.
Appointed Vishal Kapoor to board of directors.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Jasper Therapeutics, Inc. reported the fiscal year ended December 31, 2022 results: net income Net loss was $37.7 million.

Period: the fiscal year ended December 31, 2022
Net income: Net loss was $37.7 million
Result: reported results

Exact text from the filing

Jasper Therapeutics, Inc. issued a press release reporting its financial results for the fiscal year ended December 31, 2022

View on SEC.gov

19 earnings releases filed in the last 30 days. Browse all earnings releases →

Jasper Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-018537

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.